The nicotinamide/streptozotocin rodent model of type 2 diabetes: Renal pathophysiology and redox imbalance features

LJ Yan - Biomolecules, 2022 - mdpi.com
Diabetic nephropathy (DN) is a common complication of diabetes mellitus. While there has
been a great advance in our understanding of the pathogenesis of DN, no effective …

A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy

A Ashfaq, M Meineck, A Pautz, E Arioglu-Inan… - Pharmacology & …, 2023 - Elsevier
We have performed a systematic review of studies reporting on the renal effects of SGLT2
inhibitors in rodent models of diabetes. In 105 studies, SGLT2 inhibitors improved not only …

Sodium‐glucose cotransporter 2 inhibitors: a comprehensive review from cells to bedside

B Bagheri, H Yaribeygi, E Taherifard… - Fundamental & …, 2023 - Wiley Online Library
Abstract Sodium‐glucose cotransporter 2 (SGLT2) inhibitors (SGLT2is) are oral medications
approved for type 2 diabetes mellitus. Interestingly, during recent years, they have been …

Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?

A Tsankof, G Neokosmidis, E Koureta… - Frontiers in …, 2022 - frontiersin.org
Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects
a considerable proportion of the general population worldwide. Obesity is a major risk factor …

Dapagliflozin presented nonalcoholic fatty liver through metabolite extraction and AMPK/NLRP3 signaling pathway

D Lin, Y Song - Hormone and Metabolic Research, 2023 - thieme-connect.com
In recent years, the incidence rate of nonalcoholic fatty liver disease (NAFLD) has been
increasing year by year. The experiments conducted on rat elucidated the effect and …